Cargando…
Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644025/ https://www.ncbi.nlm.nih.gov/pubmed/37969120 http://dx.doi.org/10.21037/tp-23-360 |
| _version_ | 1785147192566087680 |
|---|---|
| author | Mrózek, Krzysztof |
| author_facet | Mrózek, Krzysztof |
| author_sort | Mrózek, Krzysztof |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10644025 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106440252023-11-15 Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations Mrózek, Krzysztof Transl Pediatr Editorial Commentary AME Publishing Company 2023-09-25 2023-10-30 /pmc/articles/PMC10644025/ /pubmed/37969120 http://dx.doi.org/10.21037/tp-23-360 Text en 2023 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Mrózek, Krzysztof Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title | Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title_full | Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title_fullStr | Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title_full_unstemmed | Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title_short | Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations |
| title_sort | prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/kmt2a alterations |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644025/ https://www.ncbi.nlm.nih.gov/pubmed/37969120 http://dx.doi.org/10.21037/tp-23-360 |
| work_keys_str_mv | AT mrozekkrzysztof prognosticimportanceofthefusionpartnersandmeasurableresidualdiseaseinpatientswithacutemyeloidleukemiawhoharbor11q23kmt2aalterations |